$0.74
7.00% yesterday
Nasdaq, May 20, 09:49 pm CET
ISIN
US6963891055
Symbol
PALI
Sector
Industry

Palisade Bio Inc Stock price

$0.74
+0.03 4.05% 1M
-1.70 69.80% 6M
-0.91 55.34% YTD
-5.11 87.40% 1Y
-389.26 99.81% 3Y
-3,696.91 99.98% 5Y
-1,895,399.26 100.00% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.05 7.09%
ISIN
US6963891055
Symbol
PALI
Sector
Industry

Key metrics

Market capitalization $3.53m
Enterprise Value $-3.64m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.32
P/B ratio (TTM) P/B ratio 0.61
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-13.50m
Free Cash Flow (TTM) Free Cash Flow $-11.35m
Cash position $7.23m
EPS (TTM) EPS $-8.90
P/E forward negative
Short interest 0.94%
Show more

Is Palisade Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Palisade Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Palisade Bio Inc forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Palisade Bio Inc forecast:

Buy
100%

Financial data from Palisade Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.69 5.69
6% 6%
-
- Research and Development Expense 7.80 7.80
1% 1%
-
-13 -13
3% 3%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -13 -13
4% 4%
-
Net Profit -13 -13
3% 3%
-

In millions USD.

Don't miss a Thing! We will send you all news about Palisade Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Palisade Bio Inc Stock News

Neutral
GlobeNewsWire
15 days ago
Two posters presented at Digestive Disease Week (DDW) 2025 Preclinical results indicate that PALI-2108 effectively modulates inflammatory pathways in the colon, promoting a favorable immune response Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts Carlsbad, CA, May 06, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Na...
Neutral
GlobeNewsWire
20 days ago
Carlsbad, CA, May 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it has been selected to give an oral presentation at the 3 rd Annual Precis...
Neutral
GlobeNewsWire
about one month ago
Sustained positive preliminary data from all completed single ascending dose (SAD) cohorts, multiple ascending dose (MAD) cohorts, and food effects crossover, further supporting the safety and tolerability of PALI-2108
More Palisade Bio Inc News

Company Profile

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company is headquartered in Carlsbad, CA.

Head office United States
CEO J. Finley
Employees 8
Founded 2011
Website www.palisadebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today